Company intelligence / Profile preview

Catabasis Pharmaceuticals

Boston, Massachusetts, United States

Ownership: Private
Employees: ~93
Development stage: Other

Overview

Catabasis Pharmaceuticals discontinued its lead program edasalonexent after Phase 3 failure in DMD and rebranded to Astria Therapeutics in 2021 following acquisition of Quellis Biosciences, focusing on HAE with STAR-0215 in preclinical development.

Therapeutic areas: ImmunologyPulmonologyRare Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

Jain Foundation (preclinical collaboration on edasalonexent in dysferlinopathy)Bill & Melinda Gates Medical Research Institute (CAT-5571 in tuberculosis)Duchenne UK (preclinical dysferlinopathy study)

Beyond the preview

Go deeper on Catabasis Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Catabasis Pharmaceuticals.

Explore the full profile